NASDAQ:MRSN

Mersana Therapeutics News Headlines

$14.90
-0.10 (-0.67 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.89
$15.31
50-Day Range
$13.97
$18.07
52-Week Range
$13.79
$29.09
Volume696,833 shs
Average Volume854,071 shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.46

Mersana Therapeutics (NASDAQ MRSN) News Headlines Today

SourceHeadline
Mersana Therapeutics: Return On Capital Employed InsightsMersana Therapeutics: Return On Capital Employed Insights
benzinga.com - June 8 at 6:42 PM
Mersana Therapeutics, Inc.s (NASDAQ:MRSN) CEO Will Probably Find It Hard To See A Huge Raise This YearMersana Therapeutics, Inc.'s (NASDAQ:MRSN) CEO Will Probably Find It Hard To See A Huge Raise This Year
finance.yahoo.com - June 5 at 1:45 PM
Mersana Therapeutics (NASDAQ:MRSN) Shares Gap Up to $14.39Mersana Therapeutics (NASDAQ:MRSN) Shares Gap Up to $14.39
americanbankingnews.com - May 28 at 10:32 AM
 Analysts Anticipate Mersana Therapeutics, Inc. (NASDAQ:MRSN) to Post -$0.48 Earnings Per Share Analysts Anticipate Mersana Therapeutics, Inc. (NASDAQ:MRSN) to Post -$0.48 Earnings Per Share
americanbankingnews.com - May 27 at 3:18 PM
Mersana Therapeutics to Present at Jefferies Virtual Healthcare ConferenceMersana Therapeutics to Present at Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 26 at 8:32 AM
Mersana Therapeutics (NASDAQ:MRSN) Trading Up 2.4%Mersana Therapeutics (NASDAQ:MRSN) Trading Up 2.4%
americanbankingnews.com - May 19 at 11:43 AM
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue EstimatesMersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 10 at 11:24 PM
Mersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business UpdateMersana Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 10 at 6:24 PM
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business UpdatesMersana Therapeutics to Host Conference Call Announcing First Quarter 2021 Financial Results and Business Updates
finance.yahoo.com - May 3 at 8:19 AM
Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal OfficerMersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer
finance.yahoo.com - April 26 at 9:19 AM
Is MRSN Stock A Buy or Sell?Is MRSN Stock A Buy or Sell?
finance.yahoo.com - April 19 at 8:31 PM
Notable Wednesday Option Activity: MRSN, CAR, NRZNotable Wednesday Option Activity: MRSN, CAR, NRZ
nasdaq.com - April 14 at 6:48 PM
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual MeetingMersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
finance.yahoo.com - April 10 at 12:38 PM
Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer PatientsMersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients
finance.yahoo.com - April 9 at 2:55 PM
Mersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development PathMersana Therapeutics to Host Conference Call and Webcast to Discuss the Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path
finance.yahoo.com - April 9 at 9:55 AM
Mersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studies of the Dolaflexin Platform and Upifitamab Rilsodotin (XMT-1536) in AACR Journal Molecular Cancer TherapeuticsMersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studies of the Dolaflexin Platform and Upifitamab Rilsodotin (XMT-1536) in AACR Journal Molecular Cancer Therapeutics
finance.yahoo.com - March 15 at 1:37 PM
Moving Average Crossover Alert: Mersana Therapeutics (MRSN)Moving Average Crossover Alert: Mersana Therapeutics (MRSN)
finance.yahoo.com - March 12 at 7:05 PM
Mersana Therapeutics Announces Appointment of Allene Diaz to Board of DirectorsMersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors
finance.yahoo.com - March 11 at 12:01 PM
Mersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual MeetingMersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 10 at 8:59 PM
Stoke Therapeutics to Present at the Barclays Global Healthcare ConferenceStoke Therapeutics to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - March 4 at 8:40 AM
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue EstimatesMersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
msn.com - February 26 at 9:44 AM
Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateMersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - February 26 at 9:44 AM
Mersana Therapeutics, Inc. to Host Earnings CallMersana Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - February 26 at 9:44 AM
My Bet On Mersana TherapeuticsMy Bet On Mersana Therapeutics
seekingalpha.com - February 21 at 8:35 AM
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business UpdatesMersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates
finance.yahoo.com - February 19 at 9:45 AM
Mersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare ConferenceMersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
finance.yahoo.com - February 17 at 9:08 AM
Mersana Therapeutics Breaks Below 200-Day Moving Average - Notable for MRSNMersana Therapeutics Breaks Below 200-Day Moving Average - Notable for MRSN
nasdaq.com - January 27 at 2:29 PM
Carla Poulson Joins Mersana Therapeutics as Chief Human Resources OfficerCarla Poulson Joins Mersana Therapeutics as Chief Human Resources Officer
finance.yahoo.com - January 19 at 11:51 AM
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines OperationsThe Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
markets.businessinsider.com - January 13 at 7:55 AM
Mersana: XMT-1536s Complications, New CMO, And 2H 2021s Critical CatalystMersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst
seekingalpha.com - January 12 at 10:29 PM
Why Mersana Therapeutics Stock Is Crashing TodayWhy Mersana Therapeutics Stock Is Crashing Today
finance.yahoo.com - January 5 at 2:05 PM
MRSN May 2021 12.500 callMRSN May 2021 12.500 call
uk.finance.yahoo.com - January 1 at 4:35 PM
STOK Feb 2021 60.000 callSTOK Feb 2021 60.000 call
au.finance.yahoo.com - December 28 at 9:20 AM
STOK Feb 2021 50.000 putSTOK Feb 2021 50.000 put
au.finance.yahoo.com - December 28 at 12:00 AM
Is STOK A Good Stock To Buy Now?Is STOK A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 11:09 PM
Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics ConferenceStoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
finance.yahoo.com - December 4 at 4:55 PM
The Petri Dish: Biopharma faces off with FDA and Atlas, 5AM Ventures new startupThe Petri Dish: Biopharma faces off with FDA and Atlas, 5AM Ventures' new startup
bizjournals.com - December 3 at 3:58 PM
Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual MeetingStoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting
finance.yahoo.com - November 25 at 7:41 AM
Stoke Therapeutics Announces Pricing of $97.5 Million Public OfferingStoke Therapeutics Announces Pricing of $97.5 Million Public Offering
finance.yahoo.com - November 19 at 7:20 PM
Stoke Therapeutics Announces Proposed Public OfferingStoke Therapeutics Announces Proposed Public Offering
finance.yahoo.com - November 18 at 7:05 PM
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business UpdatesStoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
finance.yahoo.com - November 12 at 7:47 AM
Mersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and PipelineMersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and Pipeline
finance.yahoo.com - November 11 at 10:10 AM
Analysts Revenue Estimates For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Are Surging HigherAnalysts' Revenue Estimates For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Are Surging Higher
finance.yahoo.com - November 10 at 7:57 AM
Mersana Therapeutics (MRSN) CEO Anna Protopapas on Q3 2020 Results - Earnings Call TranscriptMersana Therapeutics' (MRSN) CEO Anna Protopapas on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 9 at 2:57 PM
Mersana Therapeutics EPS misses by $0.02Mersana Therapeutics EPS misses by $0.02
seekingalpha.com - November 9 at 9:57 AM
MRSN Crosses Above Average Analyst TargetMRSN Crosses Above Average Analyst Target
nasdaq.com - November 6 at 12:21 PM
Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare ConferenceMersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference
finance.yahoo.com - November 4 at 9:11 AM
Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare ConferenceStoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference
finance.yahoo.com - November 2 at 9:24 AM
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business UpdatesMersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates
finance.yahoo.com - November 2 at 9:24 AM
MRSN Nov 2020 22.500 putMRSN Nov 2020 22.500 put
ca.finance.yahoo.com - October 30 at 8:49 AM
This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.